Can tumor vaccines really cure liver cancer?.
10.3760/cma.j.cn501113-20220706-00370
- VernacularTitle:肿瘤疫苗真的能治愈肝癌吗？
- Author:
Dong Bo CHEN
1
;
Pu CHEN
1
;
Hong Song CHEN
1
Author Information
1. Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Beijing 100044, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Cancer Vaccines/therapeutic use*;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Programmed Cell Death 1 Receptor;
Immunotherapy;
Lung Neoplasms/drug therapy*;
Immune Checkpoint Inhibitors;
Liver Neoplasms/drug therapy*
- From:
Chinese Journal of Hepatology
2022;30(9):918-922
- CountryChina
- Language:Chinese
-
Abstract:
In China, the incidence of liver cancer remains high. Approximately 80% of diagnosed patients are in the intermediate and advanced stages, with a high recurrence rate and poor prognosis after surgery. Therefore, substantially reducing the incidence and mortality has always been a major clinical challenge for liver cancer. In recent years, immune checkpoint inhibitor therapy represented by programmed death protein 1 (PD-1) antibody is gradually innovating the traditional paradigm of tumor treatment, but the beneficiary population in liver cancer patients is relatively limited. With the rapid development of high-throughput sequencing, proteomics and immunomics and other fields, the demand for precision medicine continues to increase. Tumor vaccines, especially derived from neoantigens, have shown promising therapeutic effects in malignant solid tumors such as melanoma and non-small cell lung cancer due to their immunogenicity. Combining the latest research reports at home and abroad, this paper emphasis on whether tumor vaccines can effectively treat or even cure liver cancer.
